高危前列腺癌前列腺及盆腔SBRT对比常规分割IMRT的急性毒性与生活质量:随机2期试验
该随机2期试验纳入121例淋巴结阴性高危前列腺癌患者,比较每周一次SBRT与常规分割IMRT的急性毒性和早期生活质量。SBRT组急性≥2级胃肠道毒性显著低于IMRT组(8.3% vs 39.0%,P<.0001),≥2级泌尿生殖毒性两组差异无统计学意义(23.3% vs 36.1%,P=.126)。早期患者报告结局支持SBRT耐受性更好。
要点
- SBRT组急性≥2级胃肠道毒性8.3%,显著低于IMRT组的39.0%(P<.0001)。
- 两组急性≥2级泌尿生殖毒性分别为23.3%与36.1%,差异无统计学意义(P=.126)。
- 1个月时IMRT组肠道生活质量下降幅度大于SBRT组(-10.4 vs -1.9,P=.0008)。
核心结论
- 每周一次前列腺及盆腔SBRT较IMRT显著降低急性胃肠道毒性,泌尿生殖安全性相当,早期患者报告结局支持SBRT。
研究设计与样本
- 随机2期试验于2019至2024年纳入121例淋巴结阴性高危前列腺癌患者,随机接受SBRT或IMRT,均联合雄激素剥夺治疗18-24个月。
- SBRT方案:前列腺40 Gy/5次每周一次,精囊腺36.25 Gy,盆腔25 Gy;IMRT方案:前列腺及盆腔50 Gy/38次每日,后前列腺加量26 Gy。
- 主要终点为放疗期间或治疗完成后120天内急性≥2级胃肠道或泌尿生殖毒性(CTCAE v4.0)。
主要发现
- 急性≥2级胃肠道毒性SBRT组8.3%,IMRT组39.0%(P<.0001)。
- 急性≥2级泌尿生殖毒性SBRT组23.3%,IMRT组36.1%(P=.126)。
- IMRT组1例发生3级腹泻,未观察到≥3级泌尿生殖事件。
- 1个月时肠道生活质量评分IMRT组下降-10.4,SBRT组下降-1.9(P=.0008);泌尿领域评分分别下降-11.3与-7.5。
- 1周时IPSS及生活质量恶化程度SBRT组低于IMRT组(+4.55 vs +7.49,P=.062;生活质量P=.029)。
关键数值与推荐
- 急性≥2级胃肠道毒性:SBRT 8.3% vs IMRT 39.0%(P<.0001)。
- 急性≥2级泌尿生殖毒性:SBRT 23.3% vs IMRT 36.1%(P=.126)。
- 1个月肠道生活质量下降:IMRT -10.4 vs SBRT -1.9(P=.0008)。
- 1周IPSS恶化:SBRT +4.55 vs IMRT +7.49(P=.062);生活质量P=.029。
临床怎么用
- 对于淋巴结阴性高危前列腺癌,每周一次前列腺及盆腔SBRT可显著减少急性胃肠道毒性,泌尿生殖毒性不劣于IMRT。
- 早期患者报告结局提示SBRT在肠道和泌尿生活质量方面耐受性更好,支持进一步3期试验验证。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) to the prostate and pelvis in high-risk prostate cancer (HR-PC) may shorten treatment, but acute toxicity and quality of life (QoL) outcomes compared with conventional fractionated intensity modulated radiation therapy (IMRT) remain uncertain. We report acute toxicity and early QoL outcomes from a randomized phase 2 trial. METHODS AND MATERIALS: Between 2019 and 2024, 121 patients with node-negative HR-PC were randomized to SBRT (40 Gy in 5 weekly fractions to prostate, 36.25 Gy to seminal vesicles, and 25 Gy to pelvis) or IMRT (76 Gy in 38 daily fractions: 50 Gy to prostate and pelvis, followed by 26 Gy prostate boost), with androgen deprivation therapy (18-24 months). The primary endpoint was acute grade ≥2 gastrointestinal (GI) or genitourinary (GU) toxicity occurring during radiation therapy or within 120 days after treatment completion (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0). Secondary endpoints included patient-reported outcomes (Expanded Prostate Cancer Index Composite, International Prostate Symptom Score). RESULTS: Baseline characteristics were balanced (median age, 72 years; 49.6% prostate-specific antigen ≥20 ng/mL; 69% Gleason ≥8). Acute grade ≥2 GI toxicity occurred in 8.3% with SBRT versus 39.0% with IMRT (P <.0001); grade ≥2 GU toxicity in 23.3% versus 36.1%, respectively (P =.126). Grade 3 diarrhea occurred in 1 patient with IMRT; no grade ≥3 GU events were observed. At 1 month, bowel QoL declined more with IMRT (-10.4) than SBRT (-1.9; P =.0008), as did urinary domain decline (-11.3 vs -7.5). At 1 week, the International Prostate Symptom Score and QoL worsened less with SBRT than with IMRT (+4.55 vs +7.49; P =.062; QoL P =.029). CONCLUSIONS: Once-weekly SBRT to the prostate and pelvis significantly reduced acute GI toxicity and provided comparable GU safety relative to IMRT, with supportive early patient-reported outcomes. These findings extend SBRT evidence to the pelvis-inclusive setting in HR-PC and support phase 3 trials.
引用
- Poon DMC, Wong K, Lam D, et al. Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42431329. doi:10.1016/j.ijrobp.2026.06.3080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。